Catechol-o-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease

Drug Development Research

Volumn 42, Issue 1, 1997, Pages 1-25

  Dingemanse, Jasper ^a  

^a Jacor Research   (Switzerland)

Author keywords

Catechol O methyltransferase; Entacapone; Levodopa; Pharmacodynamics; Pharmacokinetics; Tolcapone

Indexed keywords

3 O METHYLDOPA; ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; TOLCAPONE;

DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DYSKINESIA; HUMAN; LIVER DYSFUNCTION; MOTOR DYSFUNCTION; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; REVIEW;

EID: 0031415076     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199709)42:1<1::AID-DDR1>3.0.CO;2-I     Document Type: Review

References (159)

1. Aho P, Lindén IB, Nissinen E, Pohto P (1988a): Prevention of cysteamine-induced duodenal ulcers in rats by COMT-inhibitor. Dig Dis Sci 33:905.
2. Aho P, Lindén IB, Nissinen E, Pohto P (1988b): Gastric mucosal protection in the rat by OR-462, a novel COMT-inhibitor. Dig Dis Sci 33:897.
3. Ahtila S, Kaakkola S, Gordin A, Korpela K, Heinävaara S, Karlsson M, Wikberg T, Tuomainen P, Männistö PT (1995): Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 18:46-57.
4. Antonin KH, Ensslin-Haasis B, Bieck PR, Dollenbacher U, Nilsson E (1991): Effect of COMT inhibition by CGP 28014 (N-(6-hydroxy-2-pyridyl)-N'-di-N-propyl formamidine) on plasma dopa and 3OMD in humans. V Clin Pharmacol Ther Yokohama, Japan (Abstract):405-408.
5. Bäckström R, Honkanen E, Pippuri A, Kairisalo P, Pystynen J, Heinola K, Nissinen E, Linden IB, Männistö PT, Kaakkola S, Pohto P (1989): Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J Med Chem 32:841-846.
6. Bartholini G, Pletscher A (1975): Decarboxylase inhibitors. Pharmacol Ther 1:407-421.
7. Bieck PR, Nilsson E, Antonin KH (1990): Effect of the new selective COMT inhibitor CGP 28014A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects. J Neural Transm Suppl 32:387-391.
8. Bieck PR, Antonin KH, Farger G, Nilsson EB, Schmidt EK, Dostert P, Strolin Benedetti M, Waldmeier PC (1993): Clinical pharmacology of the new COMT inhibitor CGP 28014. Neurochem Res 18:1163-1167.
9. Borgulya J, Bruderer H, Bernauer K, Zürcher G, Da Prada M (1989): Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: Synthesis and structure-activity studies. Helv Chim Acta 72:952-968.
10. Borroni E, Zürcher G, Da Prada M (1996): Tolcapone, a new catechol-O-methyltransferase inhibitor for the improvement of levodopa therapy in Parkinson's disease. Acta Neurol Scand 94 (Suppl 167):7-8.
11. Brooks DJ (1991): PET: Its clinical role in neurology. J Neurol Neurosurg Psychiatry 54:1-5.
12. Cedarbaum JM (1987): Clinical pharmacokinetics of antiparkinsonian drugs. Clin Pharmacokinet 13:141-178.
13. Cedarbaum JM, Léger G, Reches A, Guttman M (1990): Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys. Clin Neuropharmacol 13:544-552.
14. Cedarbaum JM, Leger G, Guttman M (1991): Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: Implications for the treatment of Parkinson's disease. Clin Neuropharmacol 14:330-342.
15. Da Prada M, Keller HH, Pieri L, Kettler R, Haefely W (1984). The pharmacology of Parkinson's disease: Basic aspects and recent advances. Experientia 40:1165-1172.
16. Da Prada M, Borgulya J, Napolitano A, Zürcher G (1994a): Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect. Clin Neuropharmacol 17 (Suppl. 3):S26-S37.
17. Da Prada M, Zürcher G, Kettler R, Dingemanse J, Jorga K, Dubuis R (1994b): Remodelling the kinetics and dynamics of levodopa therapy in Parkinson's disease by inhibiting MAO-B with lazabemide and COMT with tolcapone. In Poewe W, Lees A (eds): Antiparkinson Therapy: 20 Years of Madopar®. Basel Editiones Roche, pp 93-111.
18. Da Prada M, Zürcher G, Napolitano A (1995): Tolcapone (To) inhibits both peripheral and central catechol-O-methyltransferase (COMT). Neurology 45 (Suppl. 4):A252-A253.
19. Davis TL, Roznoski M, Burns RS (1995a): Acute effects of COMT inhibition on L-dopa pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 18:333-337.
20. Davis TL, Roznoski M, Burns RS (1995b): Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 10:349-351.
21. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M, Van Brummelen P (1995a): Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 57:508-517.
22. Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M, Van Brummelen P (1995b): Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40:253-262.
23. Dingemanse J, Jorga K, Zürcher G, Fotteler B, Sedek G, Nielsen T, Van Brummelen P (1996): Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 50:47-55.
24. Dorflinger E, Yoo K (1995): Tolcapone safety and efficacy-results from phase 2 open-label extensions. Fifth Meeting of the European Neurological Society; June 17-21; Munich.
25. Dorflinger EE, Rajput A, Martin W, Saint-Hilaire M-H, Chernik D, Yoo K, Shimoun G, Pedder S, and the Tolcapone Fluctuator II Study Group (1996): Multicenter evaluation of tolcapone (Tasmar) when given together with levodopa to Parkinson disease patients who exhibit end-of-dose wearing-off. Neurology 46:A474.
26. Dupont E, Burgunder J-M, Findley JL, Olsson J-E, Dubuis R, and the Tolcapone in Parkinson's Disease Study Group (1996): Tolcapone added to L-dopa in stable parkinsonian patients. A double-blind placebo controlled study. Acta Neurol Scand 94 (Suppl 167):8.
27. Etemadzadeh E, Koskinen L, Kaakkola S (1989): Computerized rotometer apparatus for recording circling behaviour. Methods Find Exp Clin Pharmacol 11:399-407.
28. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN (1988): Motor fluctuations in Parkinson's disease: Central pathophysiologic mechanisms, part I. Ann Neurol 24:366-371.
29. Fahn S (1989): Adverse effects of levodopa in Parkinson's disease. In Calne DB (ed): Drugs for the Treatment of Parkinson's Disease. Berlin: Springer Verlag PD, pp 385-409.
30. Fahn S (1992): Adverse effects of levodopa. In: Olanow CW, Lieberman AN (eds): The Scientific Basis for the Treatment of Parkinson's Disease. Carnforth: Parthenon Publishing Group, pp 89-112.
31. Fahn S, Elton R, Members of the UPDRS Development Committee (1987): Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, Goldstein M (eds): Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ: Macmillan Health Care Information, pp 153-163, 293-304.
32. 18F]fluoro-L-dopa in human blood. J Nucl Med 29:263-269.
33. Fredriksson A, Archer T (1995): Synergistic interactions between COMT-/MAO-inhibitors and L-dopa in MPTP-treated mice. J Neural Transm 102:19-34.
34. Gervas J, Muradas B, Bazan E, Aguado E, De Yebenes J (1983): Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33:278-282.
35. Guldberg HC, Marsden CD (1975): Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 27:135-206.
36. 18F]Fluoro-L-dopa in rhesus monkey. Nucl Med Biol 22:921-927.
37. Guttman M, Leger G, Cedarbaum JM, Reches A, Woodward W, Evans A, Diksic M, Gjedde A (1992): 3-O-Methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol 31:638-643.
38. Guttman M, Leger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A (1993): Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 8:298-304.
39. Hagan RM, Raxworthy MJ, Gulliver PA (1980): Benserazide and carbidopa as substrates of catechol-O-methyltransferase: New mechanism of action in Parkinson's disease. Biochem Pharmacol 29:3123-3126.
40. Harder S, Baas H, Rietbrock S (1995): Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin Pharmacokinet 29:243-256.
41. Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986): The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22:429-436.
42. Hartvig P, Linder KJ, Tedroff J, Bjurling P, Hörnfelt K, Langström B (1992): Regional brain kinetics of 6-fluoro-(β-11C)-L-dopa and (β-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography. J Neural Transm 87:15-22.
43. Hauser R, Dorflinger E, Pedder S, Shimoun G, Yoo K, Molho E, Shale H, and the Tolcapone De Novo Study Group (1996): Tolerability and efficacy of tolcapone(Tasmar®) in untreated Parkinson's disease (PD). Mov Disord 11 (Suppl 1):147.
44. Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ (1997): Clinical trials of add-on medications in Parkinson's disease: efficacy versus usefulness. Parkinsonism Relat Disord 3:1-4.
45. Higgins G (1996): Latest news on treatments in R&D for Parkinson's disease. Inpharma 1042:9-10.
46. Hornykiewicz O, Kish SJ (1986): Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34.
47. 18F]fluorodopa in human positron emission tomographic studies. J Cereb Blood Flow Metab 11:898-913.
48. Illi A, Sundberg S, Koulu M, Scheinin M, Heinävaara S, Gordin A (1994): COMT inhibition by high-dose entacapone does not affect haemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 32:582-588.
49. Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A (1995): The effect of entacapone on the disposition and haemodynamic effects of intravenous isoproterenol and epinephrine. Clin Pharmacol Ther 58:221-227.
50. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A (1996a): Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: Effects on haemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 59:450-457.
51. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A (1996b): Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: Lack of interactions. Eur J Clin Pharmacol 51:273-276.
52. Ishikawa T, Dhawan V, Chaly T, Robeson W, Belakhlef A, Mandel F, Dahl R, Margouleff C, Eidelberg D (1996): Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: Effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab 16:854-863.
53. Jenner P, Smith LA (1993): Interaction of the COMT inhibitor entacapone with L-dopa in MPTP treated common marmosets. Can J Neurol Sci 20 (Suppl. 4):S211.
54. Jorga K, Fotteler B (1996): Clinical pharmacology of COMT-inhibitors: Differences and similarities between entacapone and tolcapone. Acta Neurol Scand 94 (Suppl. 167):8.
55. Jorga KM, Sedek G (1995): Effect of the novel COMT-inhibitor tolcapone on L-dopa pharmacokinetics when combined with different Sinemet formulations. Neurology 45 (Suppl. 4):A291.
56. Jorga K, Dingemanse J, Fotteler B, Zürcher G (1993): Pharmacokinetics-pharmacodynamics of a novel COMT inhibitor during multiple dosing regimens. Clin Pharmacol Ther 53:180.
57. Jorga KM, Dingemanse J, Fotteler B, Schmitt M, Zürcher G, Da Prada M (1994): Effect of a novel COMT-inhibitor on L-Dopa pharmacokinetics when combined with different Madopar® formulations. New Trends Clin Neuropharmacol 8:275.
58. Kaakkola S, Wurtman RJ (1992): Effects of COMT inhibitors on striatal dopamine metabolism: A microdialysis study. Brain Res 587:241-249.
59. Kaakkola S, Gordin A, Järvinen M, Wikberg T, Schultz E, Nissinen E, Pentikäinen PJ, Rita H (1990): Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol 13:436-447.
60. Kaakkola S, Gordin A, Männistö PT (1994a): General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 25:813-824.
61. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A (1994b): Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44:77-80.
62. Kaakkola S, Teräväinen H, Ahtila S, Karlsson M, Naukkarinen T, Rita H, Gordin A (1995): Entacapone in combination with standard or controlled-release levodopa/carbidopa: A clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 2:341-347.
63. Karlsson MO, Naukkarinen T, Lennernds H (1996): A population PK/ PD model for the anti-parkinsonian triple therapy: Levodopa (LD), dopadecarboxylase (DDC) inhibitor and catechol-O-methyltransferase (COMT) inhibitor. Meeting of the Population Approach Group in Europe; June 14-15; Sandwich.
64. Keränen T, Gordin A, Harjola V-P, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993): The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16:145-156.
65. Keränen T, Gordin A, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Schultz E, Seppälä L, Wikberg T (1994): Inhibition of soluble catechol-O-methyltransferase and single dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46:151-157.
66. Keränen T, Gordin A, Koulu M, Scheinin M, Antila S, Sundberg S, Wikberg T (1996): COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. J Neural Transm 103:729-736.
67. Kopin IJ (1985): Catecholamine metabolism: Basic aspects and clinical significance. Pharmacol Rev 37:333-364.
68. Kurth M (1995): Efficacy results of tolcapone at three dose levels in levodopa-treated patients with wearing-off phenomenon. Fifth Meeting of the European Neurological Society; June 17-21; Munich.
69. Kurth MC, Adler CH, St. Hilaire M, Singer C, Waters C, Chernik DA, Dorflinger E, Yoo K, and the Tolcapone Fluctuator Study GROUP I (1995): Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease (PD) experiencing end-of-dose motor fluctuations. Neurology 45 (Suppl. 4):A275-A276.
70. Kuruma I, Bartholini G, Tissot R, Pletscher A (1971): The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 12:678-682.
71. 18F]-6-Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology 42:199-203.
72. Lave Th, Dupin S, Schmitt M, Kapps M, Meyer J, Morgenroth B, Chou RC, Jaeck D, Coassolo Ph (1996): Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 26:839-851.
73. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS (1990): Nigrostriatal dopaminergic system assessed in-vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 47:1290-1298.
74. LeWitt PA (1992): Therapy with dopaminergic drugs in Parkinson's disease. In Koller WC (ed): Handbook of Parkinson's Disease, 2nd ed. New York: Marcel Dekker, pp 469-508.
75. LeWitt PA (1996): Tolcapone produces sustained improvement for Parkinson's disease patients with a stable response to levodopa. Mov Disord 11 (Suppl. 1):272.
76. Limousin P, Pollak P, Gervason-Tournier CL, Hommel M, Perret JE (1993): Ro 40-7592, a COMT inhihitor, plus levodopa in Parkinson's disease. Lancet 341:1605.
77. Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE (1995): Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 18:258-265.
78. Lindén IB, Nissinen E, Etemadzadeh E, Kaakkola S, Männistö P, Pohto P (1988): Favourable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J Pharmacol Exp Ther 247:289-293.
79. Lundström K, Tenhunen J, Tilgman C, Karhunen T, Panula P, Ulmanen I (1995): Cloning, expression and structure of catechol-O-methyltransferase. Biochim Biophys Acta 1251:1-10.
80. Lyytinen J, Kaakkola S, Teräväinen H (1996): The effect of peripheral COMT inhibition on plasma L-dopa and 3-OMD in L-dopa/DCI treated patients with Parkinson's disease. Mov Disord 11 (Suppl. 1):198.
81. Männistö PT (1994): Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1:172-179.
82. Männistö PT, Kaakkola S (1989): New selective COMT inhibitors: Useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 10:54-56.
83. Männistö PT, Kaakkola S (1990): Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66:317-323.
84. Männistö PT, Kaakkola S, Nissinen E, Linden IB, Pohto P (1988): Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 43:1465-1471.
85. Männistö PT, Tuomainen P, Tuominen RT (1992a): Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Br J Pharmacol 105:569-574.
86. Männistö PT, Ulmanen I, Lundström K, Taskinen J, Tenhunen J, Tilgmann C, Kaakkola S (1992b): Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 39:291-350.
87. Marsden CD (1994a): Parkinson's disease. J Neurol Neurosurg Psychiatry 57:672-681.
88. Marsden CD (1994b): Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 17 (Suppl. 2):S32-S44.
89. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A (1994): Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57:186-189.
90. 18-F]fluoro-L-dopa metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemi-parkinsonian monkeys. Brain Res 626:1-13.
91. Möbius HJ, Von Sprecher G, Waldmeier PC (1992): CGP 28014. Drugs Fut 17:275-277.
92. Müller T, Kuhn W, Przuntek H (1993): Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: Is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J Neural Transm Gen Sect 92:187-195.
93. Myllylä VV, and the Tolcapone in PD Study Group I (1995): Clinical efficacy of tolcapone in L-dopa-treated parkinsonian patients with 'wearing-off' phenomenon: A multicenter double-blind study. Neurology 45 (Suppl. 4):A276.
94. Myllylä W, Sotaniemi KA, Illi A, Suominen K, Keränen T (1993): Effects of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 45:419-423.
95. Napolitano A, Del Dotto P, Petrozzi L, Dell'Agnello MG, Renna M, Bonuccelli U (1996): Acute and long-term tolcapone administration improves levodopa bioavailability and motor response in parkinsonian patients. Neurology 46:A375.
96. Nissinen E, Lindén IB, Schultz E, Pohto P (1992): Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346:262-266.
97. NOMECOMT Study Group (1996): Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. A 6-month multicenter, placebo-controlled, double-blind, parallel group study. Mov Disord 11 (Suppl. 1):267.
98. Nutt JG, Fellman JH (1984): Pharmacokinetics of levodopa. Clin Neuropharmacol 7:35-49.
99. Nutt JG, Woodward WR, Gancher ST, Merrick D (1987): 3-O-Methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 21:584-588.
100. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammerstad JP, Gordin A (1994): Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44:913-919.
101. Olanow CW (1990): Oxidation reactions in Parkinson's disease. Neurology 40 (Suppl 3):32-37.
102. Parkinson Study Group (1996): The COMT inhibitor entacapone improves parkinsonian features in fluctuating patients. Mov Disord 11 (Suppl. 1):268.
103. Penafiel N, Da Prada M, Zürcher G, Mena MA, De Yebenes JG (1990): The effect of Ro 40-7592 on the peripheral metabolism of levodopa in the monkey. First International Congress Movement Disorders, April 25-27, Washington.
104. Pentikäinen PJ, Vuorela A, Järvinen M, Wikberg T, Gordin A (1989): Human pharmacokinetics of OR-462, a new catechol-O-methyltransferase inhibitor. Eur J Clin Pharmacol 36:A110.
105. Pentikäinen PJ, Saraheimo M, Vuorela A, Ottoila P, Kultalahti ER, Wikberg T (1990): Fate of nitecapone, a new catechol-O-methyltransferase inhibitor in man: A study with double isotope technique. Clin Pharmacol Ther 47:156.
106. Pérez RA, Fernández-Alvarez E, Nieto O, Piedrafita FJ (1993): Inhibition of catechol-O-methyltransferase by 1-vinyl derivatives of nitrocatechols and nitroguaiacols. Biochem Pharmacol 45:1973-1981.
107. Playford ED, Brooks DJ (1992): In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovasc Brain Metab Rev 4:144-171.
108. Pollak P (1996): Comparison of efficacy and safety of tolcapone and bromocriptine in the treatment of parkinsonian patients. Mov Disord 11 (Suppl. 1):272.
109. 18F]fluoro-L-dopa (FD) kinetics and metabolism following inhibition of catechol-O-methyltransferase (COMT) and aromatic amino acid decarboxylase (AAAD). J Neurol 242 (Suppl. 2):S15-S16.
110. Quinn N, Parkes JD, Marsden CD (1984): Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34:1131-1136.
111. Quinn N, Critchley P, Marsden CD (1987): Young-onset Parkinson's disease. Mov Disord 2:73-91.
112. Rajput A (1996): Efficacy of tolcapone in the treatment of Parkinson's disease patients experiencing wearing-off phenomenon: The North American experience. Mov Disord 11 (Suppl. 1):271.
113. Ransmayr G, Poewe W, on Behalf of the Tolcapone Study Group (1996): A multicenter double-blind placebo-controlled study of tolcapone added to levodopa in fluctuating Parkinson's disease. Mov Disord 11 (Suppl. 1):271.
114. Reches A, Fahn S (1982): 3-O-Methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12:267-271.
115. Reches A, Mielke LR, Fahn S (1982): 3-O-Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 32:887-888.
116. Reilly DK, Rivera-Calimlim L, Van Dyke D (1980): Catechol-O-methyltransferase activity: A determinant of levodopa response. Clin Pharmacol Ther 28:278-286.
117. Rivett AJ, Eddy BJ, Roth JA (1982): Contribution of sulfate conjugation, deamination, and O-methylation to metabolism of dopamine and norepinephrine in human brain. J Neurochem 39:1009-1016.
118. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN (1993): Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 43:2685-2688.
119. Ruottinen HM, Rinne UK (1996a): A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 19:283-296.
120. Ruottinen HM, Rinne UK (1996b): Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19:222-233.
121. Ruottinen HM, Rinne UK (1996c): Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60:36-40.
122. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect 10:91-106.
123. Ruottinen HM, Rinne JO, Bergman JR, Haaparanta MT, Solin OH, Ruotsalainen UH, Oikonen VJ, Rinne UK (1996): Change in fluorodopa accumulation differs in L-dopa-treated and de novo parkinsonian patients after inhibition of peripheral catechol-O-methyltransferase (COMT) and monoamine oxidase B (MAO-B). J Neurol 243 (Suppl. 2):S8.
124. 18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease. Neurology 44:1292-1297.
125. Schultz, E, Tarpila S, Bäckström AC, Gordin A, Nissinen E, Pohto P (1991): Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone. Eur J Clin Pharmacol 40:577-580.
126. Sedek G, Leese P, Burns RS, Jorga K, Schmitt M (1993): Effect of COMT inhibition on L-dopa kinetics in the presence of carbidopa. Clin Pharmacol Ther 53:180.
127. Sedek G, Jorga K, Voo K, Hood J (1996): Lack of interaction between ephedrine and combination of tolcapone and Sinemet. Neurology 46:A374.
128. Shinotoh H, Calne DB (1995): The use of PET in Parkinson's disease. Brain Cogn 28:297-310.
129. Shoulson I, Glaubiger GA, Chase TN (1975): On-off response: Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25:1144-1148.
130. Sidén Å, and the NOMECOMT Study Group (1996): A Nordic multicentre trial on entacapone in patients with Parkinson's disease and end-of-dose fluctuations. Acta Neurol Scand 94 (Suppl. 167):6.
131. Slomiany BL, Piotrowski J, Ismail A, Rajiyah G, Tamura S, Bielanski W, Slomiany A (1991): Protection against alcohol-induced gastric mucosal injury by nitecapone. Gen Pharmacol 22:1055-1062.
132. Snow BJ, Vingerhoets FJG, Holden JE, Sossi V, Buckley KR, Morrison KS, Ruth T, Jorga K, Pedder S, Dingemanse J (1996): The effect of tolcapone on central and peripheral COMT activity in normal humans and Parkinson's disease: A PET study. Mov Disord 11 (Suppl. 1):195.
133. Spatz M, Kaneda N, Sumi C, Nagatsu I, Creveling CR, Nagatsu T (1986): The presence of catechol-O-methyltransferase activity in separately cultured cerebromicrovascular endothelial and smooth muscle cells. Brain Res 381:363-367.
134. Spencer CM, Benfield P (1996): Tolcapone. CNS Drugs 5:475-481.
135. Stocchi F, Bonamartini A, Vacca L, Ruggieri S (1996): Motor fluctuations in levodopa treatment: Clinical pharmacology. Eur Neurol 36 (Suppl. 1):38-42.
136. Suchowersky O, Martin WRW, Bailey P, Argatoff P, Roberts T, Hodder J, Bailey S, Brant R (1996): Benefit of tolcapone in patients with early Parkinson's disease. Neurology 46:A159.
137. Sundberg S, Gordin A (1991): COMT inhibition with nitecapone does not affect the tyramine pressor response. Br J Clin Pharmacol 32:130-132.
138. Sundberg S, Scheinin M, Ojala-Karlsson P, Kaakkola S, Akkila J, Gordin A (1990): Exercise haemodynamics and catecholamine metabolism after COMT inhibition with nitecapone. Clin Pharmacol Ther 48:356-364.
139. Sundberg S, Scheinin M, Illi A, Akkila J, Gordin A, Keränen T (1993a): The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 36:451-456.
140. Sundberg S, Scheinin M, Ojala-Karlsson P, Akkila J, Gordin A (1993b): The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition. Eur J Clin Pharmacol 44:287-290.
141. Tedroff J, Hartvig P, Bjurling P, Andersson Y, Antoni G, Långström B (1991): Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J Neural Transm 85:11-17.
142. Tohgi H, Abe T, Kikuchi T, Takahashi S, Nozaki Y (1991): The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease. Neurosci Lett 132:19-22.
143. Tohgi H, Abe T, Yamazaki K, Saheki M, Takahashi S, Tsukamoto Y (1995): Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: Correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 192:165-168.
144. Törnwall M, Männistö PT (1993): Effects of three types of catechol-O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. Eur J Pharmacol 250:77-84.
145. Törnwall M, Tuomainen P, Männistö PT (1992): Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice. Arch Int Pharmacodyn 320:5-20.
146. Tuomainen P, Reenila I, Männistö PT (1996): Validation of assay of catechol-O-methyltransferase activity in human erythrocytes. J Pharm Biomed Anal 14:515-523.
147. Wada K, Uematsu T, Mizuno T, Kosuga K, Takiguchi H, Tsukamoto T, Tagami C, Nakajima M (1993): Pharmacodynamics and pharmacological properties of Ro 40-7592, a new catechol-O-methyltransferase inhibitor. In: Program and Abstracts of the 14th Congress of the Japanese Society of Clinical Pharmacology and Therapeutics. September 21-22, Yokohama, Abstract O-37.
148. Wade LA, Katzman R (1975): 3-O-Methyldopa inhibition of L-dopa at the blood-brain barrier. Life Sci 17:131-136.
149. Waldmeier PC, Baumann PA, Feldtrauer JJ, Hauser K, Bittiger H, Bischoff S, Von Sprecher G (1990): CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch Pharmacol 342:305-311.
150. Waters CH, Kurth MC, Shulman L, Bailey P, Shale H, Dorflinger E, Yoo K, Shimoun G, Pedder S, and the Tolcapone Stable Study Group (1996): Evaluation of the efficacy and safety of tolcapone (Tasmar) in Parkinson's disease patients with a stable response to levodopa. Neurology 46:A160.
151. Welsh MD, Ved N, Waters CH (1995): Improving quality of life in Parkinson's disease: An experimental study of tolcapone. Qual Life Res 4:503.
152. Wikberg T, Vuorela A, Ottoila P, Taskinen J (1993): Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 21:81-92.
153. Wiseman LR, McTavish D (1995): Selegiline. A review of its clinical efficacy in Parkinson's disease and its clinical potential in Alzheimer's disease. CNS Drugs 4:230-246.
154. Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, Smith ME, Titus DC (1989): Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 39 (Suppl. 2):25-38.
155. Zürcher G, Colzi A, Da Prada M (1990a): Ro 40-7592: Inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm 32:375-380.
156. Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R, Da Prada M (1990b): Ro 40-7592, a novel, very potent and orally active inhibitor of catechol-O-methyltransferase: A pharmacological study in rats. Adv Neurol 53:497-503.
157. Zürcher G, Dingemanse J, Da Prada M (1991): Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: Preclinical and clinical findings. In Agnoli A, Campanella G (eds): New Developments in Therapy of Parkinson's Disease. Rome: John Libbey, pp 37-43.
158. Zürcher G, Dingemanse J, Da Prada M (1993): Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain-preclinical and clinical findings. Adv Neurol 60:641-647.
159. Zürcher G, Da Prada M, Dingemanse J (1996): Assessment of catechol-O-methyltransferase activity and its inhibition in erythrocytes of animals and humans. Biomed Chromatogr 10:32-36.